Skip to content
DraconiticResearch
Search Sources API
203,203 studies31 sourcesUpdated 59 min ago
Peer-reviewedCC BY 4.0Journal of Cachexia, Sarcopenia and Muscle

S100A9 Mediates Neuroblastoma‐Associated Skeletal Muscle Atrophy via O‐GlcNAcylation Repression and Activate Mitophagy Activation

  • Jianwei Lin1
  • Yuxin Zhang2
  • Qi Wang3
  • Jingchun Lv1
  • Bingqiang Han4
  • Dapeng Jiang1
4 affiliations
  1. 1Department of Oncology (Ward 2), Shanghai Children's Medical Center Shanghai Jiao Tong University School of Medicine Shanghai China
  2. 2Department of Anesthesiology, Shanghai Children's Medical Center Shanghai Jiao Tong University School of Medicine Shanghai China
  3. 3Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Institute of Molecular Medicine, State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute Renji Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai China
  4. 4Department of Pediatric Orthopedics, Shanghai Children's Medical Center Shanghai Jiao Tong University School of Medicine Shanghai China
Read full textDOICite

Abstract

Background: In patients with neuroblastoma (NB), skeletal muscle atrophy is a key factor linked to poor survival and decreased long‐term quality of life. Nevertheless, there are still insufficient therapeutic methods that work, and the underlying mechanisms remain unclear. As persistent inflammation is a hallmark of tumour‐related muscle atrophy, this study aims to identify the key inflammatory mediators causing NB‐related muscle atrophy and systematically elucidate the downstream molecular mechanism.

Methods: The adverse biological features of NB were used to identify potential inflammatory mediators causing muscle atrophy. Serum samples from NB patients and NB mouse models were then used to confirm the clinical relevance of these candidates to skeletal muscle atrophy. Recombinant inflammatory proteins and certain inhibitors were given in vivo to define the functional impact of mediators. Additionally, RNA sequencing (RNA‐seq), quantitative real‐time PCR (qPCR) and Western blotting were used to methodically examine the underlying molecular pathways of NB‐induced muscle atrophy.

Results: Both NB patients with muscle atrophy and NB mouse models had considerably higher serum levels of the pro‐inflammatory mediator S100A9 protein (p < 0.001). Recombinant mouse S100A9 protein functionally reduced skeletal muscle weight and upregulated the atrophy markers TRIM63/FBXO32 in mice (p < 0.05), whereas its inhibitor, ABR‐238901, successfully reduced muscle atrophy and downregulated these atrophy markers in the NB model (p < 0.001). Mechanistically, S100A9 inhibited skeletal muscle protein O‐GlcNAcylation via its receptor RAGE (p < 0.05). Muscle atrophy was ultimately caused by the abnormal activation of BNIP3/BNIP3L‐mediated mitophagy that resulted from this suppression. Lastly, by inhibiting this mitophagy route, in vivo administration of the O‐GlcNAcylation agonist Thiamet G considerably reduced skeletal muscle atrophy in NB mice (p < 0.05).

Conclusions: Our study identifies S100A9 as a critical mediator of NB‐associated skeletal muscle atrophy through a novel RAGE/O‐GlcNAcylation/mitophagy axis, establishing S100A9 as a potential therapeutic target and providing a rationale for early interventional strategies to preserve muscle mass and improve patient outcomes.

Related

  1. High glucose drives non-small cell lung cancer progression via OGT-mediated O-GlcNAcylation and PI3K/AKT/mTOR pathway activation.
    Guo-Dong Shi, Hui-Jiang Gao, Dong Wang +2
    Translational cancer researchPeer-reviewedCC BY-NC-NDFull textMolecular biology & gene regulationEurope PMC
  2. The carbohydrate utilization regulator Cbr1 coordinates nutrient-specific gene activation with selective carbon catabolite repression in a basidiomycete yeast
    Brandon Reyes-Chavez, Joshua D. Kerkaert, Lori B. Huberman
    PLOS BiologyPeer-reviewedCC BY 4.0Full textEnzymology & metabolismMolecular biology & gene regulationPLOS
  3. Bergapten Alleviates Periodontitis by Suppressing NLRP3 Inflammasome Activation via Mitophagy-Induced Disruption of NEK7-NLRP3 Interaction.
    Xiangbin Jia, Yuzhao Wang, Jiao Cao +6
    Antioxidants (Basel, Switzerland)Peer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  4. Non-coding RNA 7SK drives tumor resistance by coupling local oncogenic activation with global transcriptional repression
    Ping Xu, Zile Luo, Xi Chen +6
    PLOS Computational BiologyPeer-reviewedCC BY 4.0Full textMolecular biology & gene regulationOncologyPLOS
  5. Chronic Intermittent Hypoxia Aggravates the Pyroptosis of Renal Tubular Epithelial Cells Through Regulating Mitophagy‐Mediated NLRP3 Inflammasome Activation
    Yuwei Zhang, Hongyan Tai
    Journal of biochemical and molecular toxicologyPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMCEurope PMCPMC

Cite

BibTeXRIS
BibTeX
@article{lin2026s100a9,
  title = {{S100A9 Mediates Neuroblastoma‐Associated Skeletal Muscle Atrophy via O‐GlcNAcylation Repression and Activate Mitophagy Activation}},
  author = {Jianwei Lin and Yuxin Zhang and Qi Wang and Jingchun Lv and Bingqiang Han and Dapeng Jiang},
  journal = {Journal of Cachexia, Sarcopenia and Muscle},
  year = {2026},
  month = nov,
  doi = {10.1002/jcsm.70419},
  url = {https://doi.org/10.1002/jcsm.70419},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - S100A9 Mediates Neuroblastoma‐Associated Skeletal Muscle Atrophy via O‐GlcNAcylation Repression and Activate Mitophagy Activation
AU  - Jianwei Lin
AU  - Yuxin Zhang
AU  - Qi Wang
AU  - Jingchun Lv
AU  - Bingqiang Han
AU  - Dapeng Jiang
PY  - 2026
DA  - 2026/11/05
JO  - Journal of Cachexia, Sarcopenia and Muscle
DO  - 10.1002/jcsm.70419
UR  - https://doi.org/10.1002/jcsm.70419
AB  - Background: In patients with neuroblastoma (NB), skeletal muscle atrophy is a key factor linked to poor survival and decreased long‐term quality of life. Nevertheless, there are still insufficient therapeutic methods that work, and the underlying mechanisms remain unclear. As persistent inflammation is a hallmark of tumour‐related muscle atrophy, this study aims to identify the key inflammatory mediators causing NB‐related muscle atrophy and systematically elucidate the downstream molecular mechanism.  Methods: The adverse biological features of NB were used to identify potential inflammatory mediators causing muscle atrophy. Serum samples from NB patients and NB mouse models were then used to confirm the clinical relevance of these candidates to skeletal muscle atrophy. Recombinant inflammatory proteins and certain inhibitors were given in vivo to define the functional impact of mediators. Additionally, RNA sequencing (RNA‐seq), quantitative real‐time PCR (qPCR) and Western blotting were used to methodically examine the underlying molecular pathways of NB‐induced muscle atrophy.  Results: Both NB patients with muscle atrophy and NB mouse models had considerably higher serum levels of the pro‐inflammatory mediator S100A9 protein (p < 0.001). Recombinant mouse S100A9 protein functionally reduced skeletal muscle weight and upregulated the atrophy markers TRIM63/FBXO32 in mice (p < 0.05), whereas its inhibitor, ABR‐238901, successfully reduced muscle atrophy and downregulated these atrophy markers in the NB model (p < 0.001). Mechanistically, S100A9 inhibited skeletal muscle protein O‐GlcNAcylation via its receptor RAGE (p < 0.05). Muscle atrophy was ultimately caused by the abnormal activation of BNIP3/BNIP3L‐mediated mitophagy that resulted from this suppression. Lastly, by inhibiting this mitophagy route, in vivo administration of the O‐GlcNAcylation agonist Thiamet G considerably reduced skeletal muscle atrophy in NB mice (p < 0.05).  Conclusions: Our study identifies S100A9 as a critical mediator of NB‐associated skeletal muscle atrophy through a novel RAGE/O‐GlcNAcylation/mitophagy axis, establishing S100A9 as a potential therapeutic target and providing a rationale for early interventional strategies to preserve muscle mass and improve patient outcomes.
SN  - 2190-5991
SN  - 2190-6009
ER  -